AVITA Medical Announces FDA Approval of RECELL GO
VALENCIA, Calif., May 30, 2024 (GLOBE NEWSWIRE) — AVITA Medical, Inc. (NASDAQ:RCEL, ASX:AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that the U.S. Food and Drug Administration (FDA) has approved its premarket approval (PMA) supplement for the RECELL GO™ System, its next-generation autologous cell harvesting device that harnesses the regenerative properties of a patient’s own skin to treat thermal burn wounds and full-thickness skin defects.